

# ForPatients

by Roche

Metastatic Solid Tumors Advanced Solid Tumors Solid Tumors

## A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

**Trial Status**  
Recruiting

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT06031441 2023-509266-38-00  
GO44431

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT06031441 2023-509266-38-00 GO44431**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---